The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
RATIONALE: Ex vivo, bronchial epithelial cells from people with asthma are more susceptible to rhinovirus infection caused by deficient induction of the antiviral protein, IFN-β. Exogenous IFN-β restores antiviral activity. OBJECTIVES: To compare the efficacy and safety of inhaled IFN-β with placebo administered to people with asthma after onset of cold symptoms to prevent or attenuate asthma symptoms caused by respiratory viruses. METHODS: A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps 2-5), with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-β (n = 72) or placebo (n = 75) within 24 hours of developing cold symptoms and were assessed clinically, with relevant samples collected to assess virus infection and antiviral responses. MEASUREMENTS AND MAIN RESULTS: A total of 91% of randomized patients developed a defined cold. In this modified intention-to-treat population, asthma symptoms did not get clinically significantly worse (mean change in six-item Asthma Control Questionnaire <0.5) and IFN-β treatment had no significant effect on this primary endpoint, although it enhanced morning peak expiratory flow recovery (P = 0.033), reduced the need for additional treatment, and boosted innate immunity as assessed by blood and sputum biomarkers. In an exploratory analysis of the subset of more difficult-to-treat, Step 4-5 people with asthma (n = 27 IFN-β; n = 31 placebo), Asthma Control Questionnaire-6 increased significantly on placebo; this was prevented by IFN-β (P = 0.004). CONCLUSIONS: Although the trial did not meet its primary endpoint, it suggests that inhaled IFN-β is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population. Clinical trial registered with www.clinicaltrials.gov (NCT 01126177).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
British Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Self-citationType I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors
Honda, K., Takaoka, A., & Taniguchi, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.009 · Cited by 1,393
Wark, P. A. B., Johnston, S. L., Bucchieri, F., Powell, R., Puddicombe, S., Laza-Stanca, V., Holgate, S. T., & Davies, D. E. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041901 · Cited by 1,235
Self-citationRole of deficient type III interferon-λ production in asthma exacerbations
Contoli, M., Message, S. D., Laza-Stanca, V., Edwards, M. R., Wark, P. A. B., Bartlett, N. W., Kebadze, T., Mallia, P., Stanciu, L. A., Parker, H. L., et al. (2006) · Nature Medicine · doi:10.1038/nm1462 · Cited by 1,006
Self-citationJuniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Corne, J. M., Marshall, C., Smith, S., Schreiber, J., Sanderson, G., Holgate, S. T., & Johnston, S. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07953-9 · Cited by 573
Self-citationJohnston, S. L., Pattemore, P. K., Sanderson, G., Smith, S., Campbell, M. J., Josephs, L. K., Cunningham, A., Robinson, B. S., Myint, S. H., Ward, M. E., et al. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.3.8810601 · Cited by 565
Self-citationCosts of asthma according to the degree of severity
Serra-Batlles, J., Plaza, V, Morejon, E., Comella, A., & Brugues, J. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.12061322 · Cited by 387
JACKSON, G. G. (1958) · A.M.A. Archives of Internal Medicine · doi:10.1001/archinte.1958.00260140099015 · Cited by 384
The role of viruses in acute exacerbations of asthma
Jackson, D. J., & Johnston, S. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.021 · Cited by 351 · cited 2×
“regular ICS since screening, and (4) postbronchodilator FEV1 greater than or equal to 35% of predicted.”
BackgroundSelf-citationViruses and bacteria in acute asthma exacerbations – A GA2LEN‐DARE* systematic review
Papadopoulos, N. G., Christodoulou, I., Rohde, G., Agache, I., Almqvist, C., Bruno, A., Bonini, S., Bont, L., Bossios, A., Bousquet, J., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02505.x · Cited by 288
Self-citationRodrigo, G. J., Neffen, H., & Castro-Rodriguez, J. A. (2011) · Chest · doi:10.1378/chest.10-1194 · Cited by 268
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237994.95410.ce · Cited by 257
Harrison, T., Oborne, J., Newton, S., & Tattersfield, A. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15384-6 · Cited by 229
Self-citationImpaired innate interferon induction in severe therapy resistant atopic asthmatic children
Edwards, M. R., Regamey, N., Vareille, M., Kieninger, E., Gupta, A., Shoemark, A., Saglani, S., Sykes, A., Macintyre, J., Davies, J., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2012.118 · Cited by 214
Self-citationSykes, A., Edwards, M. R., Macintyre, J., del Rosario, A., Bakhsoliani, E., Trujillo-Torralbo, M.-B., Kon, O. M., Mallia, P., McHale, M., & Johnston, S. L. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.03.044 · Cited by 209
Self-citationLopez-Souza, N., Favoreto, S., Wong, H., Ward, T., Yagi, S., Schnurr, D., Finkbeiner, W. E., Dolganov, G. M., Widdicombe, J. H., Boushey, H. A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.010 · Cited by 199
Predy, G. N. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041470 · Cited by 158
Cakebread, J. A., Xu, Y., Grainge, C., Kehagia, V., Howarth, P. H., Holgate, S. T., & Davies, D. E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.023 · Cited by 133
Self-citationRhinovirus-induced interferon production is not deficient in well controlled asthma
Sykes, A., Macintyre, J., Edwards, M. R., del Rosario, A., Haas, J., Gielen, V., Kon, O. M., McHale, M., & Johnston, S. L. (2014) · Thorax · doi:10.1136/thoraxjnl-2012-202909 · Cited by 129
Self-citationSimple procedures for blinded sample size adjustment that do not affect the type I error rate
Kieser, M., & Friede, T. (2003) · Statistics in Medicine · doi:10.1002/sim.1585 · Cited by 126
Bosco, A., Ehteshami, S., Stern, D. A., & Martinez, F. D. (2010) · Mucosal Immunology · doi:10.1038/mi.2010.13 · Cited by 77
Predicting worsening asthma control following the common cold
Walter, M. J., Castro, M., Kunselman, S. J., Chinchilli, V. M., Reno, M., Ramkumar, T. P., Avila, P. C., Boushey, H. A., Ameredes, B. T., Bleecker, E. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00026808 · Cited by 38
The asthma index: A continuous variable to characterize exacerbations of asthma
Sorkness, R. L., Gonzalez-Fernandez, G., Billmeyer, E. E., Evans, M. D., Gern, J. E., & Jarjour, N. N. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.07.041 · Cited by 13
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Self-citationLambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Holgate, S. T., Wenzel, S., Postma, D. S., Weiss, S. T., Renz, H., & Sly, P. D. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.25 · Cited by 652
Self-citationAsthma Exacerbations: Pathogenesis, Prevention, and Treatment
Castillo, J. R., Peters, S. P., & Busse, W. W. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.05.001 · Cited by 544
Metadata
- Authors
- Djukanović, R., Harrison, T., Johnston, S. L., Gabbay, F., Wark, P., Thomson, N. C., Niven, R., Singh, D., Reddel, H. K., Davies, D. E., Marsden, R., Boxall, C., Dudley, S., Plagnol, V., Holgate, S. T., & Monk, P.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-15
- Volume
- 190
- Issue
- 2
- Pages
- 145-154
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2150961146
- Cited by
- 266
- References
- 28
- FWCI
- 20.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.